Abstract

Tethering known drugs to a metalorganic moiety is an efficient approach for modulating the anticancer, antibacterial, and antiparasitic activity of organometallic complexes. This study focused on the synthesis and evaluation of new dinuclear ruthenium(II)–arene compounds linked to several antimicrobial compounds such as dapsone, sulfamethoxazole, sulfadiazine, sulfadoxine, triclosan, metronidazole, ciprofloxacin, as well as menadione (a 1,4-naphtoquinone derivative). In a primary screen, 30 compounds (17 hybrid molecules, diruthenium intermediates, and antimicrobials) were assessed for in vitro activity against transgenic T. gondii tachyzoites constitutively expressing β-galactosidase (T. gondii β-gal) at 0.1 and 1 µM. In parallel, the cytotoxicity in noninfected host cells (human foreskin fibroblasts, HFF) was determined by an alamarBlue assay. When assessed at 1 µM, five compounds strongly impaired parasite proliferation by >90%, and HFF viability was retained at 50% or more, and they were further subjected to T. gondii β-gal dose-response studies. Two compounds, notably 11 and 13, amide and ester conjugates with sulfadoxine and metronidazole, exhibited low IC50 (half-maximal inhibitory concentration) values 0.063 and 0.152 µM, and low or intermediate impairment of HFF viability at 2.5 µM (83 and 64%). The nature of the anchored drug as well as that of the linking unit impacted the biological activity.

Highlights

  • In the last two decades, important research in the fight against cancer was focused on the use of ruthenium compounds as alternatives to platinum drugs currently employed as therapeutics [1,2,3,4]

  • Since atovaquone (Figure 1) and buparvaquone are quinone-based antimicrobial medications for the prevention and treatment of T. gondii [69,70,72] and other parasites, we have considered the development of a small library of compounds in which the 1,4naphtoquinone motif is associated with the trithiolato diruthenium scaffold

  • This study has focused on the synthesis and in vitro evaluation of 13 new conjugates based on trithiolato-bridged ruthenium(II)–arene scaffold tethered with various antimicrobial drugs, aiming at improving the antiparasitic properties and the selectivity

Read more

Summary

Introduction

In the last two decades, important research in the fight against cancer was focused on the use of ruthenium compounds as alternatives to platinum drugs currently employed as therapeutics [1,2,3,4]. Two types of structures can be distinguished, namely symmetric complexes (Figure 1, A and A’) in which the three thiols are identical (general formula [(η 6 -p-MeC6 H4 Pri ) Ru2 (μ2 -SR)3 ]X), and mixed complexes (Figure 1, B) bearing at least one different thiol (general formula [(η 6 -p-MeC6 H4 Pri ) Ru2 (μ2 -SR1) (μ2 -SR2)]X) These compounds have been initially developed and evaluated as catalysts [22], and subsequently as cytotoxic agents. Complex A’ (R = But ) was highly active against in vitro cultured cancer cells [23,24,25,26,27], and three analogues were tested in vivo [28,29] This encouraged us to assess trithiolato diruthenium complexes as potential antiparasitic agents, and several derivatives were highly active against Toxoplasma gondii [30], Neospora caninum [31] and Trypanosona brucei [32].

Objectives
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call